367 related articles for article (PubMed ID: 36050733)
21. C1qTNF-related protein 1 attenuates doxorubicin-induced cardiac injury via activation of AKT.
Chen H; Gao L; Huang Z; Liu Y; Guo S; Xing J; Meng Z; Liang C; Li Y; Yao R; Li L; Zhang Y; Gu H; Liu Y
Life Sci; 2018 Aug; 207():492-498. PubMed ID: 29964055
[TBL] [Abstract][Full Text] [Related]
22. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.
Chang WT; Lin YW; Ho CH; Chen ZC; Liu PY; Shih JY
Arch Toxicol; 2021 Feb; 95(2):659-671. PubMed ID: 33211168
[TBL] [Abstract][Full Text] [Related]
23. Mitigation of doxorubicin-induced cardiotoxicity by dichloroacetate: potential roles of restoration of PGC-1α/SIRT3 signaling and suppression of oxidative stress and apoptosis.
Saleh MF; Elsayad ME; Goda AE
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6573-6584. PubMed ID: 34787860
[TBL] [Abstract][Full Text] [Related]
24. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products.
Yu J; Wang C; Kong Q; Wu X; Lu JJ; Chen X
Phytomedicine; 2018 Feb; 40():125-139. PubMed ID: 29496165
[TBL] [Abstract][Full Text] [Related]
25. Protective Effect of Acetyl-L-Carnitine Against Doxorubicin-induced Cardiotoxicity in Wistar Albino Rats.
Dundar HA; Kiray M; Kir M; Kolatan E; Bagriyanik A; Altun Z; Aktas S; Ellidokuz H; Yilmaz O; Mutafoglu K; Olgun N
Arch Med Res; 2016 Oct; 47(7):506-514. PubMed ID: 28262191
[TBL] [Abstract][Full Text] [Related]
26. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
27. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
[TBL] [Abstract][Full Text] [Related]
28. Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis.
Shaker RA; Abboud SH; Assad HC; Hadi N
BMC Pharmacol Toxicol; 2018 Jan; 19(1):3. PubMed ID: 29321061
[TBL] [Abstract][Full Text] [Related]
29. The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review.
Conway A; McCarthy AL; Lawrence P; Clark RA
BMC Cancer; 2015 May; 15():366. PubMed ID: 25948399
[TBL] [Abstract][Full Text] [Related]
30. Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice.
Grant MK; Seelig DM; Sharkey LC; Zordoky BN
Biol Sex Differ; 2017; 8():1. PubMed ID: 28078076
[TBL] [Abstract][Full Text] [Related]
31. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment.
Saleh Y; Abdelkarim O; Herzallah K; Abela GS
Heart Fail Rev; 2021 Sep; 26(5):1159-1173. PubMed ID: 32410142
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game.
Dos Santos Arruda F; Tomé FD; Miguel MP; de Menezes LB; Nagib PRA; Campos EC; Soave DF; Celes MRN
Curr Pharm Des; 2019; 25(2):109-118. PubMed ID: 30864503
[TBL] [Abstract][Full Text] [Related]
33. Screening for
Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
[TBL] [Abstract][Full Text] [Related]
34. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
[TBL] [Abstract][Full Text] [Related]
35. Rac1-mediated cardiac damage causes diastolic dysfunction in a mouse model of subacute doxorubicin-induced cardiotoxicity.
Ohlig J; Henninger C; Zander S; Merx M; Kelm M; Fritz G
Arch Toxicol; 2018 Jan; 92(1):441-453. PubMed ID: 28710503
[TBL] [Abstract][Full Text] [Related]
36. Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity.
Galal A; El-Bakly WM; Al Haleem EN; El-Demerdash E
Cancer Chemother Pharmacol; 2016 Feb; 77(2):309-22. PubMed ID: 26676227
[TBL] [Abstract][Full Text] [Related]
37. [Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B].
Hu KY; Yang Y; He LH; Wang DW; Jia ZR; Li SR; Tian W; Mao J; Li XJ; Zhang W
Yao Xue Xue Bao; 2014 Jul; 49(7):1007-12. PubMed ID: 25233631
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.
Tantawy M; Pamittan FG; Singh S; Gong Y
Clin Transl Sci; 2021 Jan; 14(1):36-46. PubMed ID: 32770710
[TBL] [Abstract][Full Text] [Related]
39. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
40. Alternative approach for mitigation of doxorubicin-induced cardiotoxicity using herbal agents.
Khan MA; Singh M; Khan MS; Ahmad W; Najmi AK; Ahmad S
Curr Clin Pharmacol; 2014; 9(3):288-97. PubMed ID: 23342982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
